Moderna Inc. presented new safety data from an early trial providing the first evidence that its Covid-19 vaccine stimulates the immune system of older people. In a Phase 1 trial, Moderna’s coronavirus vaccine produced “consistently high levels” of neutralizing antibodies – a key component of the body’s protective response – …
Read More »
The COVID-19 vaccine candidates developed by Moderna Inc. and BioNTech and Pfizer Inc. will require strict standards for cooling, and that may hinder how they are distributed to the hundreds of millions of Americans who expect to receive them. Shares of Modern MRNA, -3.54% were 3.6% lower in trading on …
Read More »
The rally in shares in Moderna Inc. jumped through news late Tuesday that the U.S. government ordered 100 million doses of its COVID-19 vaccine candidate on Wednesday as analysts waited for what the order meant for prices. Modern MRNA, + 1.94% is widely regarded as a front-runner in the race …
Read More »